Chlorhexidine gluconate - Generic Drug Details

What are the generic drug sources for chlorhexidine gluconate and what is the scope of patent protection?

Chlorhexidine gluconate is the generic ingredient in twenty-eight branded drugs marketed by Xttrium, Sage Prods, Medline Industries, Bajaj, Chartwell Rx, Lyne, Pharm Assoc, Pharmobedient, Sciegen Pharms Inc, Sunstar Americas, 3M, Colgate Palmolive Co, Colgate-palmolive Co, Soapco, Ecolab, Molnlycke Hlth, J And J, Matrix Medcl, Griffen, Becton Dickinson, Kendall Il, Carefusion 2200, Dexcel Pharma, 3m Health Care, Becton Dickinson Co, and Prof Dspls, and is included in thirty-six NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Chlorhexidine gluconate has three patent family members in one country.

There are twenty-seven drug master file entries for chlorhexidine gluconate. Fifty-seven suppliers are listed for this compound.

Summary for chlorhexidine gluconate

International Patents:	3
US Patents:	4
Tradenames:	28
Applicants:	26
NDAs:	36
Drug Master File Entries:	27
Finished Product Suppliers / Packagers:	57
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	178
Drug Prices:	Drug price trends for chlorhexidine gluconate
What excipients (inactive ingredients) are in chlorhexidine gluconate?	chlorhexidine gluconate excipients list
DailyMed Link:	chlorhexidine gluconate at DailyMed

See drug prices for chlorhexidine gluconate

See drug sales revenues for chlorhexidine gluconate

Recent Clinical Trials for chlorhexidine gluconate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mariam Hesham Mahmoud Abdelfattah Eissa	NA
Aydin Adnan Menderes University	PHASE4
Harran University	NA

See all chlorhexidine gluconate clinical trials

Pharmacology for chlorhexidine gluconate

Physiological Effect

Decreased Cell Wall Integrity

Medical Subject Heading (MeSH) Categories for chlorhexidine gluconate

Anti-Infective Agents, Local

Disinfectants

Mouthwashes

Anatomical Therapeutic Chemical (ATC) Classes for chlorhexidine gluconate

A01AB	Antiinfectives and antiseptics for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

B05CA	Antiinfectives
B05C	IRRIGATING SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

D08AC	Biguanides and amidines
D08A	ANTISEPTICS AND DISINFECTANTS
D08	ANTISEPTICS AND DISINFECTANTS
D	Dermatologicals

D09AA	Medicated dressings with antiinfectives
D09A	MEDICATED DRESSINGS
D09	MEDICATED DRESSINGS
D	Dermatologicals

R02AA	Antiseptics
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

S01AX	Other antiinfectives
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for chlorhexidine gluconate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ecolab	CIDA-STAT	chlorhexidine gluconate	SOLUTION;TOPICAL	019258-001	Jul 22, 1986		OTC	No	No
Griffen	BIOSCRUB	chlorhexidine gluconate	SPONGE;TOPICAL	019822-001	Mar 31, 1989		OTC	No	No
Sunstar Americas	PAROEX	chlorhexidine gluconate	SOLUTION;DENTAL	076434-001	Nov 29, 2005		DISCN	No	No
Xttrium	EXIDINE	chlorhexidine gluconate	SOLUTION;TOPICAL	019125-001	Dec 24, 1984		OTC	No	No
Pharm Assoc	CHLORHEXIDINE GLUCONATE	chlorhexidine gluconate	SOLUTION;DENTAL	074522-001	Dec 15, 1995	AT	RX	No	No
Becton Dickinson	CHLORHEXIDINE GLUCONATE	chlorhexidine gluconate	SPONGE;TOPICAL	072525-001	Oct 24, 1989		OTC	No	Yes
Xttrium	EXIDINE	chlorhexidine gluconate	AEROSOL, METERED;TOPICAL	019127-001	Dec 24, 1984		OTC	Yes	Yes

Expired US Patents for chlorhexidine gluconate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Molnlycke Hlth	HIBICLENS	chlorhexidine gluconate	SPONGE;TOPICAL	018423-001	Approved Prior to Jan 1, 1982	3,855,140
Dexcel Pharma	PERIOCHIP	chlorhexidine gluconate	TABLET;DENTAL	020774-001	May 15, 1998	5,023,082
Molnlycke Hlth	HIBICLENS	chlorhexidine gluconate	SOLUTION;TOPICAL	017768-001	Approved Prior to Jan 1, 1982	3,855,140
Sage Prods	CHLORHEXIDINE GLUCONATE	chlorhexidine gluconate	CLOTH;TOPICAL	021669-001	Apr 25, 2005	7,066,916
Dexcel Pharma	PERIOCHIP	chlorhexidine gluconate	TABLET;DENTAL	020774-001	May 15, 1998	5,002,769
Molnlycke Hlth	HIBICLENS	chlorhexidine gluconate	SPONGE;TOPICAL	018423-001	Approved Prior to Jan 1, 1982	3,886,277
Sage Prods	CHLORHEXIDINE GLUCONATE	chlorhexidine gluconate	CLOTH;TOPICAL	021669-001	Apr 25, 2005	7,595,021

International Patents for chlorhexidine gluconate

Country	Patent Number	Title	Estimated Expiration
Canada	2551688	DEBARBOUILLETTE NON TISSEE AMELIOREE (IMPROVED NON-WOVEN WASH CLOTH)
Canada	2467150	DISPOSITIF D'ADMINISTRATION DE DESINFECTANT ET METHODE DE DESINFECTION SANS ALCOOL (DISINFECTANT DELIVERY SYSTEM AND METHOD OF PROVIDING ALCOHOL-FREE DISINFECTION)
Canada	2467155	DISPOSITIF D'ADMINISTRATION DE DESINFECTANT ET METHODE DE DESINFECTION SANS ALCOOL (DISINFECTANT DELIVERY SYSTEM AND METHOD OF PROVIDING ALCOHOL-FREE DISINFECTION)

Market Dynamics and Financial Trajectory for Chlorhexidine Gluconate

Last updated: January 7, 2026

Executive Summary

Chlorhexidine gluconate (CHG) is a widely used antiseptic agent in healthcare, dentistry, and personal hygiene applications. Its market is propelled by increasing infection control needs, expanding surgical volumes, and rising awareness of antiseptic use. Forecasts indicate steady growth driven by regulatory approvals, technological advancements, and expanding applications. However, challenges such as generic competition, safety concerns, and regulatory shifts influence the market's financial trajectory.

This comprehensive analysis explores the current market landscape, key growth drivers, competitive environment, and future forecasts, enabling stakeholders to position effectively within this evolving sector.

---

What Are the Key Market Drivers for Chlorhexidine Gluconate?

Infection Control and Healthcare Policies

• Rising prevalence of healthcare-associated infections (HAIs) propels demand for antiseptics.
• Hospitals and clinics implementing strict infection prevention protocols favor CHG, especially for surgical site preparation and hand hygiene.
• Regulatory agencies, including CDC and WHO, recommend chlorhexidine-based protocols, amplifying adoption.

Expanding Applications

• Dental care: CHG is the gold standard for plaque control and periodontal disease management.
• Preoperative skin preparation: Regulatory approvals in multiple regions facilitate global adoption.
• Personal hygiene products: Increasing demand for antiseptic products in consumer markets.

Technological Innovations

• Enhanced formulations (e.g., sustained-release gels, wipes) improve efficacy and user compliance.
• Innovations targeted at reducing resistance and adverse effects.

Regulatory Approvals and Expanded Labeling

• Regulatory bodies such as FDA and EMA approving new indications expand market scope.
• Approval of new combinations and formulations increases product pipeline.

Rising Healthcare Expenditure

• Growing global healthcare budgets particularly in emerging economies boost market growth.
• Infrastructure development enhances access.

---

What Are the Challenges and Restraints in the Market?

Challenges	Details
Resistance and Efficacy Concerns	Emergence of chlorhexidine resistance complicates infection control strategies.
Safety and Side Effects	Rare adverse effects including hypersensitivity and skin reactions may limit use.
Regulatory and Patent Dynamics	Patent expirations lead to increased generic competition, impacting profit margins.
Market Saturation in Developed Regions	Mature markets face slower growth, pressuring pricing and innovation incentives.
Environmental Impact	Concerns over environmental accumulation necessitate safety regulations that could hinder growth.

---

Market Segmentation and Product Portfolio

Segment	Description	Market Share (Estimated, 2022)	Key Products / Formulations
Application	Healthcare, dental, personal hygiene	~60% (Healthcare dominant)	Solutions, gels, wipes, and impregnated dressings
Formulation	Liquid, gel, cream, wipes	Liquid (45%), Gel (35%), Others (20%)	2% CHG solution, 4% CHG gel, 10% impregnated wipes
End-User	Hospitals, dental clinics, households, industrial markets	Hospitals (~55%), Dentists (~20%)	CHG solutions, chlorhexidine-containing products for daily use
Geography	North America, Europe, Asia-Pacific, Latin America	North America (~40%), APAC (~30%)	Regional variants and formulations tailored for local needs

---

Financial Trajectory and Market Forecast

Historical Market Size and Growth (2018-2022)

Year	Global Market Size (USD Billion)	YOY Growth (%)	Notes
2018	0.78	—	Base year
2019	0.83	6.4%	Introduction of new formulations in emerging markets
2020	0.87	4.8%	Pandemic-driven demand for infection-control products
2021	0.92	5.7%	Increased healthcare expenditure in APAC
2022	1.00	8.7%	Market expansion, new approvals, and product launches

Forecasted Market Size (2023-2028)

Year	Projected Market Size (USD Billion)	CAGR (2023-2028)	Key Growth Factors
2023	1.10	9.0%	Pipeline innovations, increased adoption in emerging markets
2024	1.20	9.1%	Expanding applications, regulatory approvals
2025	1.30	8.3%	Diversification into new formulations
2026	1.45	8.5%	Greater penetration in developing markets
2027	1.60	10.0%	Post-pandemic recovery, sustained infection control emphasis
2028	1.75	9.4%	Innovation-driven growth

Note: CAGR based on historical trends and projected market drivers.

---

Competitive Landscape: Who Are the Major Players?

Company	Market Share (Estimated, 2022)	Key Products/Brands	Strategies
Johnson & Johnson	~25%	Peridex, Hibiclens	New formulation launches, regulatory expansion
Reckitt Benckiser	~20%	SoftScrub, Dettol Disinfectant	Market expansion, brand diversification
Crona LLC	~10%	Chlorhexidine products	Focused regional presence, innovation
3M	~8%	Surgical wipes and solutions	Integration with healthcare infrastructure
Others (e.g., Swisher Hygiene, Local Manufacturers)	Remaining	Various formulations	Competitive pricing, regional customization

Emerging Competitors and Innovation Trends

• Biotech firms developing sustained-release formulations.
• Entry of generics following patent expirations, increasing price competition.
• Development of combination antiseptics to combat resistance.

---

Regional Analysis

Region	Market Share (2022)	Growth Drivers	Challenges
North America	40%	Regulatory approvals, high healthcare spending	Competition from alternative antiseptics
Europe	25%	Stringent infection control standards	Regulatory hurdles, safety concerns
Asia-Pacific	30%	Large population base, expanding healthcare infrastructure	Price sensitivity, regulatory variability
Latin America	5%	Growing awareness, hospital expansion	Limited awareness, cost constraints

---

Regulatory Landscape and Policy Frameworks

1. United States (FDA)

   • Approved formulations include 2% CHG solutions for surgical disinfection.
   • Guidelines emphasize infection control standards.

2. European Union (EMA)

   • CHG classified as a biocidal product with restrictions.
   • Emphasis on safety and environmental impacts.

3. Asia-Pacific

   • Varying regulations; some markets lack stringent regulatory pathways.
   • Increasing approvals aligned with healthcare infrastructure expansion.

4. Environmental and Safety Regulations

   • Concerns over chlorhexidine's environmental persistence.
   • Regulatory bodies imposing limits on discharge and disposal.

---

Comparison with Similar Antiseptics

Parameter	Chlorhexidine Gluconate	Alcohol-based disinfectants	Iodophors (e.g., povidone-iodine)
Efficacy	Broad-spectrum, residual activity	Rapid action, limited residual activity	Broad-spectrum, limited residual
Application	Surgical prep, oral, skin cleansing	Hand sanitizers, surface disinfectants	Skin antiseptics, wound care
Safety Profile	Hypersensitivity risk, staining	Skin dryness, irritation	Allergic reactions, iodine sensitivity
Environmental Impact	Persistence concerns	Generally environmentally friendly	Potential for iodine accumulation

---

FAQs

1. What are the primary clinical applications of chlorhexidine gluconate?
   CHG is predominantly used for surgical skin preparation, hand hygiene in healthcare, dental plaque control, and preoperative skin disinfection.

2. How is the market for chlorhexidine gluconate expected to evolve in emerging economies?
   Growth is projected to be significant, driven by expanding healthcare infrastructure, increasing infection control awareness, and regulatory approvals for new indications.

3. What are the key challenges faced by market stakeholders?
   Resistance development, safety concerns leading to regulatory restrictions, patent expirations fostering generic competition, and environmental impacts are major challenges.

4. Which innovations are shaping the future of chlorhexidine gluconate?
   Sustained-release formulations, combination products with other antiseptics, and formulations tailored to specific applications are key innovation areas.

5. How do regulatory differences impact the global market for CHG?
   Variations in approval processes, safety standards, and biocidal regulations influence market entry timelines, formulation approval, and competitive strategies across regions.

---

Key Takeaways

• Market Outlook: The global chlorhexidine gluconate market is expected to grow at a CAGR of approximately 9% through 2028, reaching around USD 1.75 billion.

• Drivers: Infection control policies, expanding application scope, and technological innovations are key drivers.

• Constraints: Resistance development, safety concerns, patent expirations, and environmental regulations need strategic navigation.

• Opportunities: Emerging markets, new formulations, and regulatory approvals provide avenues for growth.

• Competitive Dynamics: Major players focus on innovation, regional expansion, and formulations tailored to local needs.

• Strategic Focus: Stakeholders should monitor regulatory policies, non-traditional applications, and environmental impacts to maintain competitive advantage.

---

References

1. [1] World Health Organization. (2021). Infection prevention and control.
2. [2] MarketsandMarkets. (2022). Antiseptics & Disinfectants Market by Type, Application, and Region.
3. [3] U.S. Food and Drug Administration. (2020). Guidelines for Surgical Skin Preparation.
4. [4] European Medicines Agency. (2022). Biocidal Products Regulation.
5. [5] Grand View Research. (2023). Chlorhexidine Market Size, Share & Trends Analysis.

Note: All figures are estimates based on market reports and industry analyses as of 2022–2023.